Chronic hepatitis B: What should be the goal for new therapies?

Antiviral Research

Volumn 98, Issue 1, 2013, Pages 27-34

  Block, Timothy M ^a,b   Gish, Robert ^c   Guo, Haitao ^a   Mehta, Anand ^a   Cuconati, Andrea ^b   Thomas London, W ^b,d   Guo, Ju Tao ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b BARUCH S BLUMBERG INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

Chronic hepatitis B; Direct acting antivirals; Hepatitis B virus

Indexed keywords

LAMIVUDINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; FOLLOW UP; GOAL ATTAINMENT; HEPATITIS B; HIGH RISK BEHAVIOR; HUMAN; LABORATORY TEST; LIFE EXPECTANCY; LIVER CANCER; LIVER CIRRHOSIS; LIVER FUNCTION; LONG TERM CARE; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOCIETY; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; VIRAL LOAD; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 84874638128     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.01.006     Document Type: Note

References (74)

1. EASL Clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009, 50:227-242.
2. Amin J., Law M.G., Bartlett M., Kaldor J.M., Dore G.J. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006, 368:938-945.
3. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61:1942-1956.
4. Belloni L., Allweiss L., Guerrieri F., Pediconi N., Volz T., Pollicino T., Petersen J., Raimondo G., Dandri M., Levrero M. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J. Clin. Invest. 2012, 122:529-537.
5. Block T.M., Guo H., Guo J.T. Molecular virology of hepatitis B virus for clinicians. Clin. Liver Dis. 2007, 11:685-706. vii.
6. Boni C., Fisicaro P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., Laccabue D., Zerbini A., Cavalli A., Missale G., Bertoletti A., Ferrari C. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 2007, 81:4215-4225.
7. Cai D., Mills C., Yu W., Yan R., Aldrich C., Saputelli J., Mason W., Xu X., Guo J.-T., Block T.M., Cuconati A., Guo H. Identification of the Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation. Antimicrob. Agents Chemother. 2012, 56:4277-4288.
8. Chan H.L., Thompson A., Martinot-Peignoux M., Piratvisuth T., Cornberg M., Brunetto M.R., Tillmann H.L., Kao J.H., Jia J.D., Wedemeyer H., Locarnini S., Janssen H.L., Marcellin P. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J. Hepatol. 2011, 55:1121-1131.
9. Chen G., Lin W., Shen F., Iloeje U.H., London W.T., Evans A.A. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol. 2006, 101:1797-1803.
10. Chen Y.C., Jeng W.J., Chu C.M., Liaw Y.F. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin. Gastroenterol. Hepatol. 2012, 10:297-302.
11. Chien R.N., Liaw Y.F., Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian hepatitis lamivudine trial group. Hepatology 1999, 30:770-774.
12. Ciupe S.M., Ribeiro R.M., Nelson P.W., Dusheiko G., Perelson A.S. The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc. Nat. Acad. Sci. 2007, 104:5050-5055.
13. Cohen C., Holmberg S.D., McMahon B.J., Block J.M., Brosgart C.L., Gish R.G., London W.T., Block T.M. Is chronic hepatitis B being undertreated in the United States?. J. Viral Hepat. 2011, 18:377-383.
14. Cohen J. The emerging race to cure HIV infections. Science 2011, 332(784-785):787-789.
15. Dienstag J.L. Hepatitis B virus infection. N. Engl. J. Med. 2008, 359:1486-1500.
16. Dougherty A.M., Guo H., Westby G., Liu Y., Simsek E., Guo J.T., Mehta A., Norton P., Gu B., Block T., Cuconati A. A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob. Agents Chemother. 2007, 51:4427-4437.
17. El-Serag H.B., Mason A.C. Risk factors for the rising rates of primary liver cancer in the United States. Arch. Intern. Med. 2000, 160:3227-3230.
18. Evans, A.E., London, W.T., Gish, R.G., Cohen, C. and Block, T.M., 2012. Chronic HBV infection outside treatment guidelines: Is treatment needed? Antivir Ther. http://dx.doi.org/10.3851/IMP2325. [Epub ahead of print].
19. Fox A.N., Jacobson I.M. Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C. Clin. Infect. Dis. 2012, 55(Suppl. 1):S16-S24.
20. Ganem D., Prince A.M. Hepatitis B infection: natural history and clinical consequences. N. Engl. J. Med. 2004, 350:1118-1129.
21. Gish R.G., Marrero J.A., Benson A.B. A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol. Hepatol. (NY) 2010, 6:1-16.
22. Guidotti L.G., Chisari F.V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 2006, 1:23-61.
23. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829.
24. Guo H., Jiang D., Ma D., Chang J., Dougherty A.M., Cuconati A., Block T.M., Guo J.T. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J. Virol. 2009, 83:847-858.
25. Heathcote E.J., Marcellin P., Buti M., Gane E., De Man R.A., Krastev Z., Germanidis G., Lee S.S., Flisiak R., Kaita K., Manns M., Kotzev I., Tchernev K., Buggisch P., Weilert F., Kurdas O.O., Shiffman M.L., Trinh H., Gurel S., Snow-Lampart A., Borroto-Esoda K., Mondou E., Anderson J., Sorbel J., Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011, 140:132-143.
26. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology 2009, 49:S156-S165.
27. Hsu P.N., Yang T.C., Kao J.T., Cheng K.S., Lee Y.J., Wang Y.M., Hsieh C.T., Lin C.W., Wu Y.Y. Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma. Liver Int. 2010, 30:1379-1386.
28. Lanford R.E., Guerra B., Chavez D.C., Hodara V.L., Zheng X., Wolfgang G., Tumas D. 100 Therapeutic efficacy of the TLR7 agonist GS-9620 for HBV chronic infection in chimpanzees. J. Hepatol. 2011, 54(Suppl. 1):S45.
29. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004, 11:97-107.
30. Lee L.Y., Tong C.Y., Wong T., Wilkinson M. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int. J. Clin. Pract. 2012, 66:342-355.
31. Lewin S.R., Ribeiro R.M., Walters T., Lau G.K., Bowden S., Locarnini S., Perelson A.S. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001, 34:1012-1020.
32. Liaw Y.F. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011, 54:E1-E9.
33. Liaw Y.F., Leung N., Kao J.H., Piratvisuth T., Gane E., Han K.H., Guan R., Lau G.K., Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008, 2:263-283.
34. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., Tanwandee T., Tao Q.M., Shue K., Keene O.N., Dixon J.S., Gray D.F., Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004, 351:1521-1531.
35. Lin C.L., Kao J.H. The clinical implications of hepatitis B virus genotype: recent advances. J. Gastroenterol. Hepatol. 2011, 26(Suppl. 1):123-130.
36. Locarnini S., Mason W.S. Cellular and virological mechanisms of HBV drug resistance. J. Hepatol. 2006, 44:422-431.
37. Lok A.S. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?. J. Gastroenterol. Hepatol. 2011, 26:221-227.
38. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
39. Lopatin U., Wolfgang G., Kimberlin R., Turnas D., Cornprost M., Chittick G., Frey C., Findlay J., Ohmstede C., Kearney B., Barnes C., McHutchinson J., Hirsch K. 737 A phase-I, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single escalating oral doses of GD-9620 in healthy subjects. J. Hepatol. 2011, 54(Suppl. 1):S296.
40. Ma H., Yang R.F., Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J. Gastroenterol. Hepatol. 2010, 25:1498-1506.
41. Mason W.S., Jilbert A.R., Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc. Natl. Acad. Sci. USA 2005, 102:1139-1144.
42. Mason W.S., Liu C., Aldrich C.E., Litwin S., Yeh M.M. Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection. J. Virol. 2010, 84:8308-8315.
43. Mason W.S., Low H.C., Xu C., Aldrich C.E., Scougall C.A., Grosse A., Clouston A., Chavez D., Litwin S., Peri S., Jilbert A.R., Lanford R.E. Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection. J. Virol. 2009, 83:8396-8408.
44. Menne S., Roneker C.A., Korba B.E., Gerin J.L., Tennant B.C., Cote P.J. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-l-arabinofuranosyl)-uracil (l-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J. Virol. 2002, 76:5305-5314.
45. Menne S., Roneker C.A., Tennant B.C., Korba B.E., Gerin J.L., Cote P.J. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology 2002, 45:237-250.
46. Menne S., Tennant B.C., Liu K.H., Ascenzi M.A., Baldwin B.H., Bellezza C.A., Cote P.J., Zheng X., Wolfgang G., Turnas D. 1114 Antiviral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection. J. Hepatol. 2011, 54(Suppl. 1):S441.
47. Michalak T.I., Hodgson P.D., Churchill N.D. Posttranscriptional inhibition of class I major histocompatibility complex presentation on hepatocytes and lymphoid cells in chronic woodchuck hepatitis virus infection. J. Virol. 2000, 74:4483-4494.
48. Moucari R., Mackiewicz V., Lada O., Ripault M.P., Castelnau C., Martinot-Peignoux M., Dauvergne A., Asselah T., Boyer N., Bedossa P., Valla D., Vidaud M., Nicolas-Chanoine M.H., Marcellin P. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49:1151-1157.
49. Noordeen F., Vaillant A., Juteau J.M., Jilbert A.R. Preclinical development of the amphipathic DNA polymer rep 9AC for the treatment of HBV infection. Global Antivir. J. 2007, vol. 3:26-27. Lahaina, Hawaii. R.F. Schinazi (Ed.).
50. Norton P.A., Menne S., Sinnathamby G., Betesh L., Cote P.J., Philip R., Mehta A.S., Tennant B.C., Block T.M. Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks. Hepatology 2010, 52:1242-1250.
51. Nowak M.A., Bonhoeffer S., Hill A.M., Boehme R., Thomas H.C., McDade H. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 1996, 93:4398-4402.
52. Oberhaus S.M., Newbold J.E. Detection of an RNase H activity associated with hepadnaviruses. J. Virol. 1995, 69:5697-5704.
53. Op den Brouw M.L., Binda R.S., Geijtenbeek T.B., Janssen H.L., Woltman A.M. The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells. Virology 2009, 393:84-90.
54. Pan C.Q., Hu K.Q., Yu A.S., Chen W., Bunchorntavakul C., Reddy K.R. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J. Viral Hepat. 2012, 19:213-219.
55. Papatheodoridis G.V., Lampertico P., Manolakopoulos S., Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J. Hepatol. 2010, 53:348-356.
56. Perrillo R.P., Gish R.G., Peters M., Keeffe E.B., Alberti A., Buti M., Cooksley W.G., Fried M.W., Hadziyannis S.J., Liaw Y.F., Naoumov N.V., Schiff E.R., Thio C.L., Tsai N., Schalm S. Chronic hepatitis B: a critical appraisal of current approaches to therapy. Clin. Gastroenterol. Hepatol. 2006, 4:233-248.
57. Poordad F., Reddy K.R., Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin. Infect. Dis. 2008, 46:78-84.
58. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
59. Seeff L.B. Sustained virologic response: Is this equivalent to cure of chronic hepatitis C?. Hepatology 2013, 57:438-440.
60. Sung J.J., Tsoi K.K., Wong V.W., Li K.C., Chan H.L. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 2008, 28:1067-1077.
61. Sung J.J., Wong M.L., Bowden S., Liew C.T., Hui A.Y., Wong V.W., Leung N.W., Locarnini S., Chan H.L. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005, 128:1890-1897.
62. Takkenberg B., Terpstra V., Zaaijer H., Weegink C., Dijkgraaf M., Jansen P., Beld M., Reesink H. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. J. Gastroenterol. Hepatol. 2011, 26:1527-1535.
63. Thimme R., Wieland S., Steiger C., Ghrayeb J., Reimann K.A., Purcell R.H., Chisari F.V. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 2003, 77:68-76.
64. Thompson A.J., Muir A.J., Sulkowski M.S., Ge D., Fellay J., Shianna K.V., Urban T., Afdhal N.H., Jacobson I.M., Esteban R., Poordad F., Lawitz E.J., McCone J., Shiffman M.L., Galler G.W., Lee W.M., Reindollar R., King J.W., Kwo P.Y., Ghalib R.H., Freilich B., Nyberg L.M., Zeuzem S., Poynard T., Vock D.M., Pieper K.S., Patel K., Tillmann H.L., Noviello S., Koury K., Pedicone L.D., Brass C.A., Albrecht J.K., Goldstein D.B., McHutchison J.G. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139(120-129):e18.
65. Thompson A.J., Nguyen T., Iser D., Ayres A., Jackson K., Littlejohn M., Slavin J., Bowden S., Gane E.J., Abbott W., Lau G.K., Lewin S.R., Visvanathan K., Desmond P.V., Locarnini S.A. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010, 51:1933-1944.
66. Tsiang M., Rooney J.F., Toole J.J., Gibbs C.S. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999, 29:1863-1869.
67. Tzeng H.T., Tsai H.F., Liao H.J., Lin Y.J., Chen L., Chen P.J., Hsu P.N. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One 2012, 7:e39179.
68. Wang C.C., Holte S., Huang M.L., Sacks S.L., Engelberg R., Ferrenberg J., Shuhart M., Corey L. Kinetics of hepatitis B viral load during 48weeks of treatment with 600mg vs 100mg of lamivudine daily. J. Viral Hepat. 2004, 11:443-447.
69. Werle-Lapostolle B., Bowden S., Locarnini S., Wursthorn K., Petersen J., Lau G., Trepo C., Marcellin P., Goodman Z., Delaney W.E., Xiong S., Brosgart C.L., Chen S.-S., Gibbs C.S., Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004, 126:1750-1758.
70. Wieland S., Thimme R., Purcell R.H., Chisari F.V. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 2004, 101:6669-6674.
71. Wursthorn K., Jung M., Riva A., Goodman Z.D., Lopez P., Bao W., Manns M.P., Wedemeyer H., Naoumov N.V. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010, 52:1611-1620.
72. Wursthorn K., Lutgehetmann M., Dandri M., Volz T., Buggisch P., Zollner B., Longerich T., Schirmacher P., Metzler F., Zankel M., Fischer C., Currie G., Brosgart C., Petersen J. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006, 44:675-684.
73. Yuen M.F., Lai C.L. Treatment of chronic hepatitis B: evolution over two decades. J. Gastroenterol. Hepatol. 2011, 26(Suppl. 1):138-143.
74. Zoulim F., Mason W.S. Reasons to consider earlier treatment of chronic HBV infections. Gut 2012, 61:333-336.